Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States.
Age Factors
Aged
Aged, 80 and over
Antibodies, Bacterial
/ blood
Cross-Sectional Studies
Ethnicity
Female
Healthcare Disparities
/ statistics & numerical data
Humans
Male
Pneumococcal Infections
/ prevention & control
Pneumococcal Vaccines
/ administration & dosage
Socioeconomic Factors
Streptococcus pneumoniae
/ immunology
United States
Vaccination Coverage
/ statistics & numerical data
Vaccines, Conjugate
/ administration & dosage
13-valent pneumococcal conjugate vaccine (PCV13)
Disparities
pneumococcal vaccination
race/ethnicity
socioeconomic status (SES)
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
25
1
2019
medline:
29
2
2020
entrez:
25
1
2019
Statut:
ppublish
Résumé
In September 2014, 13-valent pneumococcal conjugate vaccine (PCV13) was universally recommended for all US adults aged ≥65 years. Adult PCV13 coverage, including whether disparities in uptake exist, however, is not well-described. We used a monthly series of cross-sectional analyses of administrative medical and prescription claims data collected by IQVIA and linked to sociodemographic data collected by Experian to estimate overall and subpopulation-level uptake of PCV13 among US adults aged ≥65 years. Among adults aged ≥65 years, 43.3% received PCV13 by the end of November 2017. Race/ethnicity, annual household income, education status, and neighborhood urbanicity were strongly related to PCV13 uptake among adults aged ≥65 years. Lower uptake of PCV13 was observed for non-Hispanic black (36.3%) and Hispanic (30.0%) adults (vs 45.6% for non-Hispanic whites, P < .01), the poor (30.7% vs 54.2% among lowest vs highest income deciles, P < .01), adults with low educational status (33.0% vs 49.0% among those without high school education vs college educated, P < .01), and those living in rural communities (22.9%) or urban/inner-city (33.8%) areas (vs 45.8% in suburban areas, P < .01). PCV13 uptake among adults aged ≥65 occurred rapidly in the three years after universal recommendation in September 2014. Yet, poor and minority communities, rural and urban/inner-city areas, and communities with low educational attainment had substantially lower PCV13 coverage. These same populations are at increased risk of pneumococcal disease. In order to maximize the benefits of pneumococcal vaccination, further targeted and tailored interventions to increase PCV13 uptake in these underserved populations are still necessary.
Sections du résumé
BACKGROUND
In September 2014, 13-valent pneumococcal conjugate vaccine (PCV13) was universally recommended for all US adults aged ≥65 years. Adult PCV13 coverage, including whether disparities in uptake exist, however, is not well-described.
METHODS
We used a monthly series of cross-sectional analyses of administrative medical and prescription claims data collected by IQVIA and linked to sociodemographic data collected by Experian to estimate overall and subpopulation-level uptake of PCV13 among US adults aged ≥65 years.
RESULTS
Among adults aged ≥65 years, 43.3% received PCV13 by the end of November 2017. Race/ethnicity, annual household income, education status, and neighborhood urbanicity were strongly related to PCV13 uptake among adults aged ≥65 years. Lower uptake of PCV13 was observed for non-Hispanic black (36.3%) and Hispanic (30.0%) adults (vs 45.6% for non-Hispanic whites, P < .01), the poor (30.7% vs 54.2% among lowest vs highest income deciles, P < .01), adults with low educational status (33.0% vs 49.0% among those without high school education vs college educated, P < .01), and those living in rural communities (22.9%) or urban/inner-city (33.8%) areas (vs 45.8% in suburban areas, P < .01).
CONCLUSIONS
PCV13 uptake among adults aged ≥65 occurred rapidly in the three years after universal recommendation in September 2014. Yet, poor and minority communities, rural and urban/inner-city areas, and communities with low educational attainment had substantially lower PCV13 coverage. These same populations are at increased risk of pneumococcal disease. In order to maximize the benefits of pneumococcal vaccination, further targeted and tailored interventions to increase PCV13 uptake in these underserved populations are still necessary.
Identifiants
pubmed: 30676236
doi: 10.1080/21645515.2018.1564434
pmc: PMC6605819
doi:
Substances chimiques
13-valent pneumococcal vaccine
0
Antibodies, Bacterial
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
841-849Références
Pharmacotherapy. 2001 Sep;21(9):1115-22
pubmed: 11560201
Public Health Rep. 2011 Sep-Oct;126 Suppl 3:81-8
pubmed: 21836741
Am J Public Health. 2005 Feb;95(2):312-23
pubmed: 15671470
Am J Public Health. 2010 Oct;100(10):1904-11
pubmed: 20724687
Ethn Dis. 2005 Spring;15(2 Suppl 3):S3-7-S3-12
pubmed: 15945360
Am J Med. 2003 Jan;114(1):31-8
pubmed: 12543287
MMWR Morb Mortal Wkly Rep. 2017 Jul 14;66(27):728-733
pubmed: 28704347
J Gen Intern Med. 2016 Aug;31(8):901-8
pubmed: 26976292
Am J Public Health. 1993 Dec;83(12):1751-3
pubmed: 8259810
Am J Prev Med. 2006 Aug;31(2):150-8
pubmed: 16829332
MMWR Recomm Rep. 2000 Mar 24;49(RR-1):1-13
pubmed: 15580726
Am J Public Health. 2003 Dec;93(12):2074-8
pubmed: 14652337
J Health Hum Serv Adm. 2003 Fall;26(2):199-238
pubmed: 15330490
BMC Med Ethics. 2017 Mar 1;18(1):19
pubmed: 28249596
MMWR Morb Mortal Wkly Rep. 2016 Oct 07;65(39):1065-1071
pubmed: 27711036
N Engl J Med. 2015 Mar 19;372(12):1114-25
pubmed: 25785969
Clin Infect Dis. 2015 May 1;60(9):1308-16
pubmed: 25747410
MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):822-5
pubmed: 25233284
J Immigr Minor Health. 2012 Apr;14(2):350-5
pubmed: 22512007
MMWR Morb Mortal Wkly Rep. 2013 Feb 1;62(4):66-72
pubmed: 23364272
Clin Infect Dis. 2017 Nov 13;65(11):1806-1812
pubmed: 29020164
Vaccine. 2009 Jul 9;27(32):4252-6
pubmed: 19406181
Clin Infect Dis. 2018 Oct 30;67(10):1498-1506
pubmed: 29790925
MMWR Surveill Summ. 2016 Feb 05;65(1):1-36
pubmed: 26844596
Hum Vaccin Immunother. 2019;15(3):584-593
pubmed: 30352017
JAMA. 2000 Jul 5;284(1):53-9
pubmed: 10872013
Br J Gen Pract. 2002 Sep;52(482):717-8, 720-2
pubmed: 12236274
Epidemiology. 2017 Jan;28(1):119-126
pubmed: 27541841
J Am Geriatr Soc. 2004 Jan;52(1):25-30
pubmed: 14687311
Vaccine. 2003 Mar 28;21(13-14):1510-7
pubmed: 12615448
J Infect Dis. 2005 Aug 1;192(3):377-86
pubmed: 15995950
Prev Med. 2002 Feb;34(2):235-41
pubmed: 11817920
MMWR Suppl. 2013 Nov 22;62(3):65-8
pubmed: 24264492
Am J Public Health. 2003 Feb;93(2):324-9
pubmed: 12554594
Am J Med. 1996 Dec;101(6):612-20
pubmed: 9003108
Am J Prev Med. 2004 Aug;27(2):153-60
pubmed: 15261903
JAMA. 1999 Aug 18;282(7):646-50
pubmed: 10517717
Can J Public Health. 1994 Jul-Aug;85 Suppl 1:S14-30
pubmed: 7987755
Am J Manag Care. 2007 Oct;13(10):581-8
pubmed: 17927463
Vaccine. 2011 Aug 11;29(35):5970-7
pubmed: 21708206
Am J Prev Med. 2010 Oct;39(4):287-95
pubmed: 20837278
J Immigr Minor Health. 2017 Aug;19(4):779-789
pubmed: 27480159
Ann Fam Med. 2012 Nov-Dec;10(6):538-46
pubmed: 23149531
Am J Infect Control. 2005 Dec;33(10):563-70
pubmed: 16330304
Hum Vaccin Immunother. 2016;12(1):206-12
pubmed: 26376039
MMWR Surveill Summ. 2017 Jan 13;66(2):1-7
pubmed: 28081057
J Am Geriatr Soc. 2006 Feb;54(2):303-10
pubmed: 16460383
MMWR Suppl. 2014 Apr 18;63(1):7-12
pubmed: 24743661